The current push to develop treatments and possibly a vaccine for covid-19 is testing all elements of the research landscape, but it’s arguably placing the efforts of universities and other institutes under particular scrutiny.
In the UK, Oxford University has been one of those leading the charge and as IAM recently exclusively revealed that has led the famed academic institution to a new and expedited licensing policy for covid-19 related IP.
